BioSpace News Archive

Akebia Therapeutics has submitted a Formal Dispute Resolution Request with the FDA regarding the rejection of vadadustat in anemia due to chronic kidney disease.

Intercept Pharmaceuticals, Inc. announced that results from two analyses assessing the potential of obeticholic acid to improve outcomes for patients with primary biliary cholangitis, including death, liver transplant and hepatic decompensation, will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases.

One in five people who survive cardiopulmonary resuscitation after cardiac arrest may describe lucid experiences of death that occurred while they were seemingly unconscious and on the brink of death, a new study shows.

Amgen presented end-of-treatment data from its Phase 2 OCEAN-DOSE study of investigational olpasiran in adults with elevated lipoprotein [Lp] levels and a history of atherosclerotic cardiovascular disease.

Asieris Pharmaceuticals announced that Hexvix®, a drug used for the diagnosis for bladder cancer, completed the first patient dose in Phase III bridging trial.

New, independently evaluated data presented at the American Heart Association’s Scientific Sessions show that use of the chronic care digital platform, Onduo by Verily, led to clinically significant improvements in blood glucose and cholesterol levels among participants of an employer-sponsored type 2 diabetes management program within the first year of participation.

Ascentage Pharma announced that it has released results from a Phase I study of the investigational inhibitor of apoptosis protein antagonist APG-1387 in Chinese patients with chronic hepatitis B, in an oral presentation at the 73rd American Association for the Study of Liver Diseases Annual Meeting.

Vir Biotechnology, Inc. announced new data from its robust hepatitis B virus portfolio aimed at achieving a functional cure.

Lexicon Pharmaceuticals, Inc., announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational heart failure treatment sotagliflozin, was presented at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois.

Telix Pharmaceuticals Limited today announced highly positive top-line results from the pivotal Phase III ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89Zr-DFO-girentuximab). The study has met its co-primary and secondary endpoints.